Yano, S
Takehara, K
Kishimoto, H
Tazawa, H
Urata, Y
Kagawa, S
Bouvet, M
Fujiwara, T
Hoffman, R M
Article History
Received: 30 September 2016
Revised: 17 October 2016
Accepted: 18 October 2016
First Online: 20 January 2017
Competing interests
: YU is the President & CEO of Oncolys BioPharma, Inc., the manufacturer of OBP-401 (Telomescan). HT and TF are consultants of Oncolys BioPharma, Inc. The remaining authors declare no conflict of interest.